News

Reader based multiplex lateral flow assays are opening new opportunities for biomarker signatures, structured data capture and algorithmic interpretation. This article explores how candidate markers can be assessed, translated into lateral flow and developed into reliable diagnostic systems with the reader, software, manufacture and regulatory pathway considered from the start.

Performance verification helps assay developers generate controlled, traceable evidence to support analytical performance claims, regulatory submissions and product launch. Fleet Bioprocessing provides CRO support for assay performance verification, claim support, study planning, protocol development, execution and reporting.

Rapid antibody screening can help identify stronger antibody candidates earlier in immunoassay development. Fleet supports antibody screening across lateral flow, ELISA, Gyrolab™ and other assay formats, with small-volume screening approaches and in-house bioconjugation capability to support better assay decisions.

Sustainability in lateral flow testing is broader than material substitution. This article explores how material design, reagent strategy, manufacturing yield, performance testing, supply chain choices and at-source testing can reduce waste across the full lateral flow test lifecycle.